Exelixis Begins Phase 3 Pivotal Trial Of Cabozantinib In Patients With MRCC – RTT News
Exelixis Begins Phase 3 Pivotal Trial Of Cabozantinib In Patients With MRCCRTT NewsExelixis Inc. (EXEL: Quote) announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcin…